AR114294A1 - Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1 - Google Patents

Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1

Info

Publication number
AR114294A1
AR114294A1 ARP180103513A ARP180103513A AR114294A1 AR 114294 A1 AR114294 A1 AR 114294A1 AR P180103513 A ARP180103513 A AR P180103513A AR P180103513 A ARP180103513 A AR P180103513A AR 114294 A1 AR114294 A1 AR 114294A1
Authority
AR
Argentina
Prior art keywords
immunoassays
proteins
control points
immune control
antibody treatments
Prior art date
Application number
ARP180103513A
Other languages
English (en)
Original Assignee
Grifols Diagnostic Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Diagnostic Solutions Inc filed Critical Grifols Diagnostic Solutions Inc
Publication of AR114294A1 publication Critical patent/AR114294A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Proteínas de fusión que comprenden un dominio extracelular de las proteínas PD-1 (proteína-1 de la muerte celular programada) y/o PD-L1 (CD274 o B7-H1) recombinante. Las partes de los dominios extracelulares se expresan en configuraciones específicas y se purifican como proteína y se utilizan en inmunoensayos para monitorizar los niveles circulantes de anticuerpos bioterapéuticos respecto a estas proteínas. También se describe un procedimiento para detectar y monitorizar un anticuerpo terapéutico en una muestra biológica obtenida de un paciente, en el que un paciente ha recibido, al menos, una dosis de inmunoterapia.
ARP180103513A 2017-11-30 2018-11-29 Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1 AR114294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762593080P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
AR114294A1 true AR114294A1 (es) 2020-08-19

Family

ID=64665106

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103513A AR114294A1 (es) 2017-11-30 2018-11-29 Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1

Country Status (9)

Country Link
US (2) US11919938B2 (es)
EP (1) EP3512874A2 (es)
JP (3) JP6967578B2 (es)
KR (2) KR20190065234A (es)
CN (1) CN110167959A (es)
AR (1) AR114294A1 (es)
TW (1) TW201925241A (es)
UY (1) UY37986A (es)
WO (1) WO2019106592A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102171766B1 (ko) * 2018-02-02 2020-10-29 주식회사 뉴라클제네틱스 Pd-l1 결합력이 증대된 pd-1 변이체
KR20230125672A (ko) * 2022-02-21 2023-08-29 사회복지법인 삼성생명공익재단 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
AU2002252978B9 (en) 2001-01-18 2007-02-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
CN101830986A (zh) 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9409950B2 (en) * 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
DK2670847T3 (en) * 2011-02-03 2017-01-16 Xoma Technology Ltd Methods and Materials for Improving Functional Protein Expression in Bacteria
CN102836441B (zh) 2011-06-24 2019-06-11 台北荣民总医院 于感染性与恶性疾病的治疗中提升免疫反应的方法
KR20150135148A (ko) 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
BR112016027897A2 (pt) * 2014-06-18 2017-10-24 Albert Einstein College Medicine Inc polipeptídio multimérico, ácido nucleico, vetor de expressão recombinante, célula hospedeira geneticamente modificada, composição, método, e, método de tratamento de uma infecção num indivíduo
AU2015292678B2 (en) * 2014-07-22 2020-10-22 Cb Therapeutics, Inc. Anti-PD-1 antibodies
US10981991B2 (en) * 2015-09-29 2021-04-20 Shanghai Zhangjiang Biotechnology Co., Ltd. PD-1 antibodies and uses thereof
CN105999223B (zh) 2016-04-26 2020-05-12 中国人民解放军第四军医大学 PDL1-IgGFc融合蛋白抑制重症疟疾发病的应用
AU2017357944A1 (en) * 2016-11-10 2019-06-20 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof

Also Published As

Publication number Publication date
JP2023068027A (ja) 2023-05-16
US20240124549A1 (en) 2024-04-18
JP2020504075A (ja) 2020-02-06
TW201925241A (zh) 2019-07-01
UY37986A (es) 2019-03-29
KR20210035915A (ko) 2021-04-01
JP6967578B2 (ja) 2021-11-17
US11919938B2 (en) 2024-03-05
WO2019106592A2 (en) 2019-06-06
US20200299353A1 (en) 2020-09-24
KR20190065234A (ko) 2019-06-11
WO2019106592A3 (en) 2019-07-18
EP3512874A2 (en) 2019-07-24
JP2022023168A (ja) 2022-02-07
CN110167959A (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
CL2020000039A1 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes. (divisional solicitud 201700647)
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
CL2019000261A1 (es) Polipéptidos modificados y usos de los mismos.
MD3601358T2 (ro) Anticorpi anti-TREM2 și metode de utilizare a acestora
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
BR112017003620A2 (pt) métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
GB2562406A (en) A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
AR114294A1 (es) Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
EA202091239A1 (ru) Слитый белок на основе терапевтического фермента, имеющий новую структуру, и его применение
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
MX2018013372A (es) Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos.
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo
UY37752A (es) Proteínas de unión al antígeno anti-jagged1